Merck & Co [MRK] vs Medicus Pharma [MDPLD] Detailed Stock Comparison

Merck & Co., Inc.

NYSE
Loading...

Medicus Pharma Ltd.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Merck & Co., Inc. wins in 9 metrics, Medicus Pharma Ltd. wins in 2 metrics, with 1 ties. Merck & Co., Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Merck & Co., Inc. Medicus Pharma Ltd. Better
P/E Ratio (TTM) 15.74 -1.47 Merck & Co., Inc.
Price-to-Book Ratio 5.39 3.90 Medicus Pharma Ltd.
Debt-to-Equity Ratio 95.96 0.10 Medicus Pharma Ltd.
PEG Ratio -0.82 N/A N/A
EV/EBITDA 10.97 0.00 Tie
Profit Margin (TTM) 28.08% 0.00% Merck & Co., Inc.
Operating Margin (TTM) 32.77% 0.00% Merck & Co., Inc.
EBITDA Margin (TTM) 32.77% N/A N/A
Return on Equity 36.88% -841.91% Merck & Co., Inc.
Return on Assets (TTM) 12.04% -358.37% Merck & Co., Inc.
Free Cash Flow (TTM) $12.36B $-4.16M Merck & Co., Inc.
Dividend Yield 2.91% N/A N/A
1-Year Return 45.70% N/A N/A
Price-to-Sales Ratio (TTM) 4.35 N/A N/A
Enterprise Value $319.41B $0 Merck & Co., Inc.
EV/Revenue Ratio 4.91 N/A N/A
Gross Profit Margin (TTM) 66.15% N/A N/A
Revenue per Share (TTM) $26 $0 Merck & Co., Inc.
Earnings per Share (Diluted) $7.28 $-2.54 Merck & Co., Inc.
Beta (Stock Volatility) 0.28 N/A N/A
Short % of Float 1.12% N/A N/A

Merck & Co., Inc. vs Medicus Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

MRK
MDPLD

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Merck & Co., Inc.-3.49%-3.87%3.16%-0.46%14.60%7.94%
Medicus Pharma Ltd.1.78%0.00%0.00%0.00%0.00%0.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Merck & Co., Inc.45.70%8.90%55.40%123.23%252.74%262.85%
Medicus Pharma Ltd.N/AN/AN/AN/AN/AN/A

Performance & Financial Health Analysis: Merck & Co., Inc. vs Medicus Pharma Ltd.

MetricMRKMDPLD
Market Information
Market Cap i$283.10BN/A
Market Cap CategoryMega capN/A
10 Day Avg. Volume i9,732,99820,091
90 Day Avg. Volume i9,710,04936,712
Last Close$114.90$2.86
52 Week Range$76.66 - $125.14$1.80 - $6.00
% from 52W High-8.18%-52.33%
All-Time High$134.63 (Jun 24, 2024)$3.00 (Jan 24, 2025)
% from All-Time High-14.65%-4.67%
Growth Metrics
Quarterly Revenue Growth0.05%N/A
Quarterly Earnings Growth-0.21%N/A
Financial Health
Profit Margin (TTM) i0.28%0.00%
Operating Margin (TTM) i0.33%0.00%
Return on Equity (TTM) i0.37%-8.42%
Debt to Equity (MRQ) i95.960.10
Cash & Liquidity
Book Value per Share (MRQ)$21.26$0.73
Cash per Share (MRQ)$5.89N/A
Operating Cash Flow (TTM) i$16.47B$-4,987,008
Levered Free Cash Flow (TTM) i$11.89B$-6,784,140
Dividends
Last 12-Month Dividend Yield i2.91%N/A
Last 12-Month Dividend i$3.32N/A

Valuation & Enterprise Metrics Analysis: Merck & Co., Inc. vs Medicus Pharma Ltd.

MetricMRK (Apr 24, 2026)MDPLD (Mar 31, 2025)
Price Ratios
P/E Ratio (TTM) i15.74-1.47
Forward P/E i11.80N/A
PEG Ratio i-0.82N/A
Price to Sales (TTM) i4.35N/A
Price to Book (MRQ) i5.393.90
Market Capitalization
Market Capitalization i$283.10B$22.45M
Enterprise Value i$319.41B$0
Enterprise Value Metrics
Enterprise to Revenue i4.91N/A
Enterprise to EBITDA i10.970.00
Risk & Other Metrics
Beta i0.28N/A
Book Value per Share (MRQ) i$21.26$0.73

Financial Statements Comparison: Merck & Co., Inc. vs Medicus Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMRK (2025)MDPLD (2023)
Revenue/Sales i65.01B0
Cost of Goods Sold i16.38BN/A
COGS % of Revenue i25.2%-
Gross Profit i48.63BN/A
Gross Margin i74.8%-
Research & Development i15.79B193,578
Operating Income (EBIT) i22.11B-3.01M
Operating Margin i34.0%-
EBITDA i29.11B-6.72M
EBITDA Margin i44.8%-
Pre-Tax Income i21.07B-6.78M
Pre-Tax Income % of Revenue i32.4%-
Income Tax i2.80BN/A
Income Tax % of Revenue i4.3%-
Net Income (Profit) i18.26B-6.78M
Profit Margin i28.1%-

Balance Sheet & Liquidity Metrics

MetricMRK (2025)MDPLD (2023)
Cash & Equivalents i14.57B1.72M
Total Current Assets i43.52B1.89M
Total Current Assets % of Revenue i66.9%-
Total Current Liabilities i28.33B1.09M
Total Current Liabilities % of Revenue i43.6%-
Long-Term Debt i46.75BN/A
Long-Term Debt % of Revenue i71.9%-
Total Shareholders Equity i52.66B805,800
Retained Earnings i73.08B-19.18M
Retained Earnings % of Revenue i112.4%-
Property, Plant & Equipment i0N/A

Cash Flow Statement Comparison

MetricMRK (2025)MDPLD (2023)
Operating Cash Flow i18.49B-4.99M
Operating Cash Flow % of Revenue i28.4%-
Capital Expenditures iN/AN/A
Free Cash Flow i12.36B-4.16M
FCF Margin i19.0%-
Debt Repayment i-2.50BN/A
Common Stock Repurchase i-5.08BN/A

Short Interest & Institutional Ownership Analysis

MetricMRKMDPLD
Shares Short i27.72MN/A
Short Ratio i2.69N/A
Short % of Float i1.12%N/A
Shares Outstanding i2.47B8.08M
Float Shares i2.47BN/A
% Held by Insiders i0.06%55.81%
% Held by Institutions i81.44%0.00%
% Held by Public i18.50%44.19%

Dividend Analysis & Yield Comparison: Merck & Co., Inc. vs Medicus Pharma Ltd.

MetricMRKMDPLD
Last 12-Month Dividend i$3.32N/A
Last 12-Month Dividend Yield i2.91%N/A
3-Year Avg Annual Dividend i$3.16N/A
3-Year Avg Dividend Yield i0.77%N/A
3-Year Total Dividends i$9.48N/A
Ex-Dividend DateMar 16, 2026N/A